{
    "clinical_study": {
        "@rank": "80801", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety issues pertaining to dihydrexidine (DHX), to\n      cocaine, and to its interaction, and to determine how pretreatment with DHX modifies the\n      subjective as well as physiological effects of cocaine infusion."
        }, 
        "brief_title": "Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13", 
        "condition": "Cocaine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the\n        study and sign informed consent.\n\n        Exclusion Criteria:\n\n        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant\n        and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.\n        Acute hepatitis. Other medical condtions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000348", 
            "org_study_id": "NIDA-3-0010-13", 
            "secondary_id": "Y01-3-0010-13"
        }, 
        "intervention": {
            "intervention_name": "Dihydrexidine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dihydrexidine"
        }, 
        "lastchanged_date": "August 16, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Infusion Laboratory: Protocol 4 (Dihydrexidine)", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": [
            {
                "measure": "Degree of drug craving"
            }, 
            {
                "measure": "Frequency of IV drug use and sexual risk behaviors"
            }, 
            {
                "measure": "History, incidence and amount of drug use"
            }, 
            {
                "measure": "Type and severity of stimulant withdrawal symptoms"
            }, 
            {
                "measure": "Characterization of study population"
            }, 
            {
                "measure": "Population incidence of symptoms of depression, po"
            }, 
            {
                "measure": "Evidence of change in neurophysiology and brain ac"
            }, 
            {
                "measure": "Evidence of change in subjective responses to coca"
            }, 
            {
                "measure": "Clinical physiological response to cocaine challen"
            }, 
            {
                "measure": "Degree to which study medication influences change"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000348"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2002"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}